Case Series – Significant Leak Reduction: 20 Subjects, who had been incontinent for an average of 10 years, treated with Elitone for 6 weeks. They maintained leak diaries and completed quality-of-life assessments (I-QoL). [READ ABSTRACT]
• 95% had reduced leaks
• 75% had clinically significant reduced leaks (> 50%)
• 71% average reduction in leaks
• I-QoL improved by 14.6 pts (>2.5 pt is clinically significant)
• 67% reduced pad use, clinically significantly (>50%)
Ultrasound Visualization – Measurable Pelvic Floor Contraction: Subjects self-applied the Elitone device. Transabdominal ultrasound images were obtained of the bladder and pelvic floor under Elitone stimulation, while performing a Kegel contraction, and while doing both simultaneously. Image analysis revealed that with Elitone the pelvic floor moved with a similar direction and magnitude to correctly performed Kegels. Further, a subject with no measurable pelvic floor movement with an attempted Kegel, achieved desirable movement with Elitone. [READ ABSTRACT]
Randomized Controlled Trial – Significant Difference from Sham: 48 Subjects self-administered 12 weeks of treatment with either the Elitone device or a sham device. Baseline characteristics were established for leaks/day, pad use, incontinence related quality of life (I-QoL), and a 24-hour pad weight test. Post-study results were compared to baseline considering absolute change, percent change, and responder rate using recognized thresholds for clinical significance. Leaks reduced by 52.8%, which is notably more than the 31.7% improvement rate from a meta analysis of intravaginal stimulation studies.
Prospective Trial – Urge Incontinence: With the new Elitone URGE device, 32 subjects were randomized between two device configurations. 97% of women improved. 85% of women were responders with over 50% improvement. All 22 questions of the I-Quality of Life tool improved, in total a 26.7 point improvement (10x greater than what FDA considers clinically significant.) Results were presented at the SUFU conference in 2023.